HCV replication and statin pleotropism: An adjuvant treatment panacea?

Dawn M. Torres, Stephen A. Harrison

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


With optimal treatment regimens for hepatitis C still under investigation, novel agents that may improve sustained virologic response (SVR) are needed. The targeting of host lipid metabolism, particularly via the cholesterol-lowering 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statins, represents a novel approach to hepatitis C therapy and has been proven beneficial in vitro. The study in this issue of the Journal is the first prospective trial that shows benefit, albeit modest, of statin therapy in vivo. While limited by heterogeneous patient population and overall small numbers, this study provides hope that use of statins in combination with standard therapy pegylated interferon and ribavirin may improve SVR.

Original languageEnglish
Pages (from-to)1390-1392
Number of pages3
JournalAmerican Journal of Gastroenterology
Issue number6
StatePublished - Jun 2008
Externally publishedYes


Dive into the research topics of 'HCV replication and statin pleotropism: An adjuvant treatment panacea?'. Together they form a unique fingerprint.

Cite this